At the 2025 ASCO Genitourinary Cancers Symposium, researchers presented updated findings from the phase 1/2 KEYMAKER-U03 Substudy 03B, evaluating pembrolizumab (pembro) and targeted therapy combinations for previously treated advanced ccRCC.
Key Findings:
Lenvatinib + belzutifan (VEGF-TKI + HIF-2α inhibitor) demonstrated durable antitumor activity, supporting further investigation in advanced RCC.
The safety profile was consistent with the known individual drug profiles, though grade 3-5 treatment-related adverse events were reported in all study arms.
The study provides new perspectives on optimizing treatment strategies for patients progressing after PD-(L)1 and VEGF-TKI therapies.
These results reinforce the importance of ongoing research in ccRCC to refine targeted therapy combinations. More insights are expected from the LITESPARK-011 trial evaluating lenvatinib + belzutifan further.
Thanks to all the researchers for their valuable contributions to advancing renal cancer treatment!
For more details: https://lnkd.in/e2SpWQ-q
